BiotechTV - News - TopPodcast.com

Latest Episodes:

London based IMU Biosciences announced today that it will use its immune system profiling platform with 80,000 blood samples from UK Biobank to create a large-scale picture of the human immune system Oct 19, 2026

Show notes

CEO John Baker describes how the project, done in collaboration with Ultima Genomics and Waters Corporation, will give researcher a tool to better understand the immune system. He also describes how IMU's blood sample based system works, and how it has been used for things such as to better understand which patients will respond to cancer immunotherapies.

Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1 Oct 15, 2026

Show notes

CEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company's pipeline progress.

At Dana-Farber Cancer Institute in Boston, President & CEO Ben Ebert and Professor and Investigator Cigall Kadoch discuss the latest trends in cancer research Oct 14, 2026

Show notes

They discuss recent advances, what's ahead, Cigall's work in epigenetics, and how a new hospital will be purpose built for patients with the best new technologies in clinical research.

Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more Oct 07, 2026

Show notes

From the company's headquarters in Indianapolis, he describes where he thinks the obesity field could be headed in the next few years, what might be next after beta-amyloid in Alzheimer's, and how he plans to invest for the future.

After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress Oct 05, 2026

Show notes

He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out.

Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease Oct 02, 2026

Show notes

CEO Markus Warmuth walks us through the data and provides a broader update on the pipeline progress at Monte Rosa and for the field of degraders and molecular glues more broadly.

From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung Sep 29, 2026

Show notes

CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO's recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity.

From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage Sep 28, 2026

Show notes

Co-Founder & Partner Sascha Oliver Bucher describes the firm and investments it has been making, and shares his thoughts on the VC ecosystem in Europe.

From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections Sep 28, 2026

Show notes

CEO David Veitch discusses Cresemba and Zevtera, both of which have momentum in what used to be market with structural barriers to commercial success, but no longer are in most geographies. Plus, a key phase 3 that will read out for Basilea's next mold infection program, fosmanogepix, in 2028.

Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study Sep 21, 2026

Show notes

Chris Hollowood, Founder of Beacon and CEO of Syncona, describes the top line result and its significance. This is the first pivotal trial in X-linked retinitis pigmentosa to achieve its primary endpoint.

Our TOPPODCAST Picks

Follow Us

Stay Connected

BiotechTV – News

Related Podcasts

Links

Stay Connected